国产午夜福利片1000无码丨人妻国产成人久久av免费高清丨午夜做受视频试看6次丨日韩av不卡一区在线免费观看丨在线观看精品三级欧美

Your Good Partner in Biology Research

Human C4 binding protein,C4BP ELISA Kit

  • 中文名稱:
    人C4結合蛋白(C4BP)酶聯免疫試劑盒
  • 貨號:
    CSB-E11170h
  • 規格:
    96T/48T
  • 價格:
    ¥3200/¥2500
  • 促銷:
  • 其他:

產品詳情

  • 產品描述:
    人C4結合蛋白(C4BP)酶聯免疫試劑盒(CSB-E11170h)為雙抗夾心法ELISA試劑盒,定量檢測血清、血漿樣本中的C4BPA含量。C4BPA作為一個靶點,其它在補體系統等生理過程中發揮作用。在研究機制上,科研人員聚焦于其在疾病發生發展中的信號通路、與其他分子的相互作用,以此探索它作為治療靶點的可能性,為相關疾病藥物研發提供方向。試劑盒檢測范圍為39 ng/ml- 2500 ng/ml,適用于基礎醫學研究中對補體系統功能分析、疾病機制探索及生物標志物篩選等科研場景,為探索免疫調控網絡或藥物干預效果提供可靠工具本品僅用于科研,不用于臨床診斷,產品具體參數及操作步驟詳見產品說明書。
  • 別名:
    C4b-binding protein alpha chain ELISA Kit; C4bp ELISA Kit; C4bpa ELISA Kit; C4BPA_HUMAN ELISA Kit; Complement component 4 binding protein alpha ELISA Kit; Complement component 4 binding protein ELISA Kit; Proline-rich protein ELISA Kit; PrP ELISA Kit; RP11-164O23.4 ELISA Kit
  • 縮寫:
  • Uniprot No.:
  • 種屬:
    Homo sapiens (Human)
  • 樣本類型:
    serum, plasma
  • 檢測范圍:
    39 ng/ml - 2500 ng/ml
  • 靈敏度:
    9.75 ng/mL
  • 反應時間:
    1-5h
  • 樣本體積:
    50-100ul
  • 檢測波長:
    450 nm
  • 研究領域:
    Immunology
  • 測定原理:
    quantitative
  • 測定方法:
    Sandwich
  • 精密度:

    Intra-assay Precision (Precision within an assay): CV%<8%

    Three samples of known concentration were tested twenty times on one plate to assess.

    Inter-assay Precision (Precision between assays): CV%<10%

    Three samples of known concentration were tested in twenty assays to assess.

  • 線性度:

    To assess the linearity of the assay, samples were spiked with high concentrations of human C4BP in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

     

    Sample

    Serum(n=4)

    1:100

    Average %

    92

    Range %

    87-96

    1:200

    Average %

    95

    Range %

    90-99

    1:400

    Average %

    90

    Range %

    85-96

    1:800

    Average %

    93

    Range %

    89-98

  • 回收率:

    The recovery of human C4BP spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

    Sample Type

    Average % Recovery

    Range

    Serum (n=5)

    98

    94-103

    EDTA plasma (n=4)

    89

    82-95

  • 標準曲線:

    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

    ng/ml

    OD1

    OD2

    Average

    Corrected

    2500

    2.931

    2.812

    2.872

    2.736

    1250

    2.457

    2.349

    2.403

    2.267

    625

    1.678

    1.628

    1.653

    1.517

    312.5

    0.860

    0.816

    0.838

    0.702

    156.25

    0.490

    0.467

    0.479

    0.343

    78

    0.321

    0.317

    0.319

    0.183

    39

    0.199

    0.189

    0.194

    0.058

    0

    0.141

    0.131

    0.136

     

  • 數據處理:
  • 貨期:
    3-5 working days

產品評價

靶點詳情

  • 功能:
    Controls the classical pathway of complement activation. It binds as a cofactor to C3b/C4b inactivator (C3bINA), which then hydrolyzes the complement fragment C4b. It also accelerates the degradation of the C4bC2a complex (C3 convertase) by dissociating the complement fragment C2a. Alpha chain binds C4b. It interacts also with anticoagulant protein S and with serum amyloid P component.
  • 基因功能參考文獻:
    1. The rs73079108 polymorphism in the 5' upstream region of C4BPA was associated with EH, and rs73079108A may be an independent predictor. PMID: 28627632
    2. INDEED also identified some candidates previously reported to be relevant to HCC, such as intercellular adhesion molecule 2 (ICAM2) and c4b-binding protein alpha chain (C4BPA), which were missed by both Differential expression and differential network analyses PMID: 27592383
    3. Exposure to arterial blood pressure leads to a transient presence of C4bp in the saphenous vein wall. PMID: 28163174
    4. Proteomics study showed a strong association of FN1, A2M, C4BPA and CFB in molecular subtypes of breast cancer, in which, C4BPA and A2M demonstrated a potent signature in blood plasma and tissue samples of Luminal-B (LB) and Triple-negative (TN)subtypes in BC patients, respectively. PMID: 27498393
    5. genetic polymorphism is associated with spontaneous abortion; review PMID: 26658464
    6. whereas the presence of plasminogen did not affect the factor I cofactor activity of C4BP, the activation of plasminogen by urokinase-type plasminogen activator to active plasmin was significantly augmented in the presence of C4BP. PMID: 26067271
    7. C4BPB/C4BPA may not confer susceptibility to schizophrenia among Han Chinese PMID: 25660618
    8. these data suggest that when C4BP is bound to Ail, fI can cleave and inactivate C4b that has bound covalently to bacterial surface structures as well as C4b bound noncovalently to Ail. PMID: 24760758
    9. In patients treated with tacrolimus and mycophenolate mophetil as a maintenance immunosuppression, the lower C4d urinary excretion in early post-transplant period seems to be a low significance prognostic marker of a better long-term kidney outcome. PMID: 24779215
    10. mutations in women experiencing recurrent miscarriages PMID: 23508668
    11. The heptameric core structure is stabilized by intermolecular disulfide bonds. PMID: 23274142
    12. C4BP alpha7beta0 isoform complement control protein-6 domain of C4BP alpha-chain is necessary for tolerogenic activity of the acute-phase C4BPbeta chain. PMID: 23390292
    13. The Lsa30 (LIC110870) is a novel adhesin that binds plasminogen and the complement regulator C4bp. PMID: 22732096
    14. Human pneumococcal glycolytic enzyme enolase, a nonclassical cell surface and plasminogen-binding protein, is a pneumococcal C4BP-binding protein. PMID: 22925928
    15. NC4 Domain of cartilage-specific collagen IX inhibits complement directly due to attenuation of membrane attack formation and indirectly through binding and enhancing activity of complement inhibitors C4B-binding protein and factor H. PMID: 21659506
    16. C4BP is recruited to the S. aureus surface where it functions to inhibit C4 complement effectors, suggesting a previously undescribed immune evasion strategy for this pathogen. PMID: 22333221
    17. Human pentraxin 3 binds to the complement regulator c4b-binding protein. PMID: 21915248
    18. Serum C4BP level in 89 patients showed a strong association with the clinical staging of non small cell lung carcinoma. PMID: 21262398
    19. C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies. PMID: 20212171
    20. Binding of the classical pathway inhibitor, C4b-binding protein (C4bp), to three genospecies of B. burgdorferi sensu lato, is demonstrated. PMID: 20022381
    21. Data show that C4BP does not bind CD40, but it forms stable high molecular weight complexes with soluble CD40 ligand (sCD154). PMID: 17225862
    22. structural requirements for the intracellular subunit polymerization PMID: 12135356
    23. Localization of binding sites for a number of C4BP ligands in relation to well-established and novel functions of C4BP. Review PMID: 15179322
    24. To determine the regions of C4b contributing to C4BP binding, the binding of the C4c and C4dg subfragments of C4b to C4BP was examined. PMID: 16819837
    25. Non-small cell lung cancer (NSCLC) cells produce soluble complement inhibitors factor I (FI) and C4b-binding protein (C4BP). PMID: 17548110
    26. The binding sites to Neisseria gonorrhoeae Por1A protein have been mapped within complement control protein domain 1 of C4BP. PMID: 17579075
    27. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. PMID: 18424762
    28. C4BP binds to dead brain cells and Abeta peptide in vitro, is present in CSF and possibly protects against excessive complement activation in AD brains. PMID: 18556068
    29. These results reinforce the case for the occupation of some of the seven arms of C4BP in a multivalent interaction with DNA or surface bound glycosaminoglycans while other arms engage C4b or C3b. PMID: 18715646
    30. Mainly the central core of C4BP mediates binding to small leucine-rich repeat proteins (SLRPs). Binding of SLRPs to C4BP does not not affect its ability to inhibit complement. PMID: 19155499
    31. isoforms of a group B streptococcus-secreted component named Fib displayed differential binding capacities for fibronectin, fibrinogen, and C4BP PMID: 19417080
    32. C4BP binding varies between strains but is dependent on the expression of pneumococcal surface protein C, PspC of group 4 PMID: 19494311
    33. The primary binding site on C4bp is located on the alpha-chain complement control protein 4 (CCP4) domain which, unlike C4bp alpha-chain amino-terminal CCP1 and CCP2, is not involved in complement regulatory activity. PMID: 11441101

    顯示更多

    收起更多

  • 亞細胞定位:
    Secreted.
  • 組織特異性:
    Chylomicrons in the plasma.
  • 數據庫鏈接:

    HGNC: 1325

    OMIM: 120830

    KEGG: hsa:722

    STRING: 9606.ENSP00000356037

    UniGene: Hs.1012



主站蜘蛛池模板: 东丰县| 通道| 额敏县| 霍州市| 托克逊县| 水城县| 景宁| 江川县| 嘉祥县| 明溪县| 海门市| 商城县| 喀喇沁旗| 甘谷县| 象山县| 清水县| 什邡市| 邻水| 贵南县| 五常市| 东海县| 长春市| 元阳县| 桐梓县| 乐昌市| 大荔县| 波密县| 汨罗市| 永川市| 元江| 黄石市| 成都市| 遵义市| 维西| 丹凤县| 大关县| 隆子县| 银川市| 榆林市| 崇阳县| 克什克腾旗|